The Danish pharmaceutical company behind drugs including Ozempic has shelved plans to build a plant in west Dublin.
In a statement, Novo Nordisk said the decision comes after "an assessment" of the project at Grange Castle Business Park in Clondalkin.
A spokesperson told Newstalk the company is now officially withdrawing its current planning applications.
"Following an assessment, Novo Nordisk has made the decision to stop project activities in Grange Castle Business Park in Ireland," they said.
"As a consequence, we will withdraw our planning application and not complete the acquisition of the land.
"We thank our partners in Ireland for their strong support and look forward to continuing our presence and collaboration in the country, including at our recently acquired Athlone facility, which will provide Novo Nordisk with additional development and manufacturing capacity for current and future oral products."
The Novo Nordisk logo on flags. Image: Novo NordiskAs first reported by The Sunday Times, Novo Nordisk said it plans to expand at its Athlone facility where it employs 400 people.
It purchased the site from biopharmaceutical company Alkermes last year, with both firms entering into subcontracting arrangements for certain work through to the end of 2025.
Ozempic improves the way your body responds to food by producing more insulin, slowing down the rate at which your stomach empties and reducing the ability of your liver to produce sugar by itself.
Research has also suggested it can cut a person’s risk of dying from heart disease by 20%.
The five-year study by University College London tracked the health of 17,604 adults over the age of 45 from 41 countries and concluded it had a positive impact on patients’ cardiovascular health.
